Author

Brian Latimer

Feist-Weiller Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

Ana‐Maria DragoiiD· 2 shared Craig R. RoyiD· 1 shared David Custis· 1 shared Magdalena L. CircuiD· 1 shared Nilu Dhungel· 1 shared Reneau Castore· 1 shared Stanimir S. IvanoviD· 1 shared Stephanie R. ShamesiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Ana‐Maria DragoiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Legionella pneumophila type IVb secretion system effector BinA subverts amino acid transport to sensitize TORC1 signaling in macrophages

Magdalena L. Circu, Reneau Castore, Brian Latimer, Stephanie R. Shames, Craig R. Roy, Ana‐Maria Dragoi, Stanimir S. Ivanov

This paper identifies BinA, a Legionella effector that rewires amino acid transport to sensitize mTORC1 signaling in macrophages, enhancing bacterial replication.

PLoS Pathogens · Jun 8, 2026Peer-reviewedMicrobiology

Direct interaction between cancer cells and fibroblasts promotes early chemoresistance to standard-of-care drug therapy in small cell lung cancer (SCLC)

Nilu Dhungel, Brian Latimer, David Custis, Ana‐Maria Dragoi

This study shows direct contact between SCLC cells and fibroblasts causes early chemoresistance to etoposide and cisplatin, with idarubicin remaining effective.

bioRxiv · Apr 30, 2026 · PreprintCancer Biology